Access reports, webinars, and recordings related to the BIO International Convention here!
Presented by Inova
The BIO International Convention is the world’s largest partnering event with 1,100 meetings happening every hour. Inova has crunched the 2016 BIO Convention partnering data and put together this white paper to help you maximize your meetings at the BIO Convention.
Check out this white paper to:
• Understand the opportunities and challenges of partnering at the BIO Convention
• Benchmark your performance at the BIO Convention using insights from BIO 2016
• Learn 12 best practices for increasing your meetings
*Latest Annual Report* 3rd Annual Emerging Therapeutic Company Investment and Deal Trends 2007-2016
More than 90% of our industry is made up of small companies. This report captures stats for companies with less than a $1 billion in sales and covers six main areas: venture funding, public investment (IPOs and follow-ons), licensing, M&A, and the clinical pipeline (partnered vs. partnered).
May 25 - Pharma Trends in Emerging Markets
Learn more about the promise of emerging markets by looking at the activity and trends in the pharmaceutical industry in Brazil, Russia, India, China and South Korea (BRICS).
May 16 - Applying Competitive Intelligence to Navigate the Changing Disease Landscape
In preparation for the 2017 BIO International Convention, Clarivate Analytics and BIO have teamed up to offer this free webinar where we will use neurodegenerative disease as a use case to demonstrate the critical information and analysis needed to be first in class and/or best in class for a therapy area. David Dunn, US Practice Lead and Scientific Advisor for Portfolio and Licensing, Clarivate Analytics will analyze the pipelines of three leading neurodegenerative diseases: Alzheimer’s, Parkinson’s and ALS. In this webinar David will examine current therapeutic hypotheses and the industry’s track record in finding therapies based on them.
May 12 - Surfing the CNS Pipeline: Ripples, Swells, or Waves
While media attention tends to be focused upon CNS clinical misses, particularly when they involve Alzheimer’s disease modifying therapies, several CNS programs have recently generated data that portend paradigm shifts in the treatment of diseases with significant unmet need. Novel treatments have shown proof-of-concept and more in Spinal Muscular Atrophy, Super-Refractory Status Epilepticus, Rett Syndrome, Treatment-Resistant Depression, Progressive MS, and rare pediatric epilepsies. Looking forward, there are additional clinical-stage programs that promise to change the standard of care and reset the bar for compounds that follow (e.g., those of GW Pharma, Alder Pharma, AveXis, Quartet Medicine, Wave Life Sciences). This is in contrast to some high-profile programs which seem more likely to be additions to the current and still marginal standard of care than true clinical breakthroughs.
We've collaborated with Yelp to create a local guidebook or explore the links below!